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Abstract
Targeted therapies based on biomarker profiling are becoming a mainstream di-
rection of cancer research and treatment. Depending on the expression of specific
prognostic biomarkers, targeted therapies assign different cancer drugs to subgroups of
patients even if they are diagnosed with the same type of cancer by traditional means,
such as tumor location. For example, Herceptin is only indicated for the subgroup
of patients with HER2+ breast cancer, but not other types of breast cancer. How-
ever, subgroups like HER2+ breast cancer with effective targeted therapies are rare
and most cancer drugs are still being applied to large patient populations that in-
clude many patients who might not respond or benefit. Also, the response to targeted
agents in human is usually unpredictable. To address these issues, we propose SUBA,
subgroup-based adaptive designs that simultaneously search for prognostic subgroups
and allocate patients adaptively to the best subgroup-specific treatments throughout
the course of the trial. The main features of SUBA include the continuous reclas-
sification of patient subgroups based on a random partition model and the adaptive
allocation of patients to the best treatment arm based on posterior predictive proba-
bilities. We compare the SUBA design with three alternative designs including equal
randomization, outcome-adaptive randomization and a design based on a probit re-
gression. In simulation studies we find that SUBA compares favorably against the
alternatives.
KEY WORDS: Adaptive designs; Bayesisan inference; Biomarkers; Posterior; Sub-
group identification; Targeted therapies.
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1 Introduction
1.1 Targeted Therapy
With the rapid development in genomics and personalized medicine it is becoming increas-
ingly more feasible to diagnose and treat cancer based on measurements from genomic inter-
rogations at the molecular level such as gene expression (Van De Vijver et al., 2002; Snijders
et al., 2001), DNA copy numbers (Curtis et al., 2012; Baladandayuthapani et al., 2010), and
epigenetic marks (Wang et al., 2008; Barski and Zhao, 2009; Mitra et al., 2013). In particular,
pairing genetic traits with targeted treatment options has been an important focus in recent
research. This has led to successful findings such as the use of trastuzumab, doxorubicin, or
taxanes on HER2+ breast cancer (Hudis, 2007), and the recommendation against treatment
with EGFR antibodies on KRAS mutated colorectal cancer (Misale et al., 2012). It is now
broadly understood that patients with the same cancer defined by classification criteria such
as tumor location, staging, and risk-stratification can respond differently to the same drug,
depending on their genetic profiling.
First proposed by Simon and Maitournam (2004), “targeted designs” restrict the eligibil-
ity of patients to receive a treatment based on predicted response using genomic information.
Under fixed sample sizes and comparing to standard equal randomization with two-arm tri-
als, the authors showed that targeted designs could drastically increase the study power in
situations where the new treatment benefited only a subset of patients and those patients
could be accurately identified. Sargent et al. (2005) proposed the biomarker-by-treatment
interaction design and a biomarker-based-strategy design, both using prognostic biomarkers
to facilitate treatment allocations to targeted subgroups. Maitournam and Simon (2005) fur-
ther showed that the relative efficiency of target designs depended on (1) the relative sizes of
the treatment effects in biomarker positive and negative subgroups, (2) the prevalence of the
patient group who favorably responds to the experimental treatment, and (3) the accuracy
of the biomarker evaluation. Recently, new designs have been proposed by Freidlin et al.
(2010), Simon (2010) and Mandrekar and Sargent (2010), among others.
BATTLE (Kim et al., 2011) and I-SPY 2 (Barker et al., 2009) are two widely known
biomarker cancer trials using Bayesian designs. The design of BATTLE predefined five
biomarker groups on the basis of 11 biomarkers, and assigned patients to four drugs using
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an outcome-adaptive randomization (AR) scheme. AR is implemented with the expectation
that an overall higher response rate would be achieved relative to equal randomization (ER),
assuming at least one biomarker group has variations in the outcome distributions across
arms. However, the analysis of the trial data revealed otherwise; the response rate was
actually slightly lower during the AR period than during the initial ER period. This fact
can be attributed to several factors such as possible trends in the enrolled population, or
variations in the procedures for measuring primary outcomes. In practice, targeted agents
can fail for reasons such as having no efficacy on the targeted patients, being unexpectedly
toxic, or uniformly ineffective. There is a need for adaptive designs to accommodate the
situations above to improve trial efficiency and maintain trial ethic (Yin et al., 2012; Gu and
Lee, 2010; Zhu et al., 2013).
Researchers are also developing new designs that allow for the redefinition of biomarker
groups that could be truly responsive to targeted treatments. Ruberg et al. (2010) and
Foster et al. (2011) developed tree-based algorithms to identify and evaluate the subgroup
effects by searching the covariate space for regions with substantially better treatment effects.
Bayesian models are natural candidates for adaptive learning of subgroups, and have been
known and applied in non-medical contexts (Loredo, 2003; Kruschke, 2008).
1.2 A Subgroup-Based Adaptive Design
In this paper, we propose a class of SUbgroup-Based Adaptive (SUBA) designs for targeted
therapies which utilize individual biomarker profiles and clinical outcomes as they become
available.
To understand and characterize a clinical trial design it is useful to distinguish between
the patients in the trial versus future patients. There exist a number of methods that address
the optimization for the patients in the trial. Most approaches are targeting the optimization
of a pre-selected objective function (criterion). See, for example, (Fedorov and Leonov, 2013,
chapters 8 and 9). SUBA aims to address both goals, successful treatment of patients in
the trial and optimizing treatment selection for future patients. We achieve the earlier by
allocating each patient on the basis of the patient’s biomarker profile x to the treatment
with the best currently estimated success probability. That is, the optimal treatment t∗ for
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a patient with biomarker profile x is
t∗(x) = arg max
t∈Ω
θˆt(x),
where θˆt(x) is the posterior predictive response rate of a patient with biomarker profile x un-
der treatment t. This can be characterized as a stochastic optimization problem. In contrast,
the optimal treatment selection for future patients is not considered as an explicit criterion
in SUBA. It is indirectly addressed by partitioning the biomarker space into subsets with
different response probabilities for the treatments under consideration. Learning about the
implied patient subpopulations facilitates personalized treatment selection for a future pa-
tient on the basis of the patient’s biomarker profile x. The outcome of SUBA is an estimated
partition of the biomarker space and the corresponding optimal treatment assignments.
The main assumption underlying the proposed design approach is that there exist sub-
groups of patients who differentially respond to treatments. For example, consider a scenario
with two subgroups of patients that respond well to either of two different treatments, but
not both. An ideal design should search for such subgroups and link each subgroup with its
corresponding superior treatment. That is, a design should aim to identify subgroups with
elevated response rates to particular treatments. The key innovations of SUBA are that such
biomarker subgroups are continuously redefined based on patients’ differential responses to
treatments and that patients are allocated to the currently estimated best treatment based
on posterior predictive inference.
In summary, SUBA conducts subgroup discovery, estimation, and patient allocation
simultaneously. We propose a prior for the partition that classifies tumor profiles into
biomarker subgroups. The stochastic partition has the advantage that biomarker subgroups
are not fixed up front before patients accrual. The goal is to use the data, during the trial,
to learn which partitions are likely to be relevant and could potentially become clinically
useful. We define a random partition of tumor profiles using a tree-based model that shares
similarities with Bayesian CART algorithms (Chipman et al., 1998; Denison et al., 1998).
We provide closed-form expressions for posterior computations and describe an algorithm
for adaptive patient allocation during the course of the trial.
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1.3 Motivating Trial
We consider a breast cancer trial with three candidate treatments. Patients who are eligible
have undergone neoadjuvant systemic therapy (NST) and surgery. Protein biomarkers for
all patients are measured through biopsy samples by reverse phase protein arrays (RPPA) at
the end of NST, but before surgery. The first treatment is a poly (ADP-ribose) polymerase
(PARP) inhibitor, which affects DNA repair and cell death programming. The second treat-
ment is a PI3K pathway inhibitor, which affects cell growth, proliferation, cell differentiation
and ultimate survival. The third treatment is a cell cycle inhibitor that targets the cell cycle
pathway. The main goal is to identify for each of the three treatments subgroups of patients
that will respond favorably to the respective treatment.
The paper proceeds as follows. Section 2 presents the probability model of SUBA design
and computation details for implementing the design. Section 3 examines the operating
characteristics based on simulation studies. We conclude with a brief discussion in Section
4.
2 Methodology
2.1 Sampling Model
Assume that T candidate treatments are under consideration in a clinical trial. We use
t ∈ Ω = {1, . . . , T} to index the treatments and i = 1, . . . , N to index patients. We assume
a maximum sample size of N patients. The primary outcome for each patient is a binary
variable yi ∈ {0, 1}. We assume that yi can be measured without delay. We denote with
xi = (xi2, . . . , xiK)
′ the biomarker profile of the i-th patient, recorded at baseline. We assume
that all biomarkers xik are continous, xik ∈ R. Finally, let zi denote the treatment allocation
for patient i with zi = t if patient i is assigned to treatment t.
The underlying assumption of a biomarker clinical trial is that there exist subgroups of
patients that differentially respond to the same treatment. For example, subgroup 1 may re-
spond well to treatment t1 but not t2 while subgroup 2 may respond well to treatment t2 but
not t1. However, the subgroups are not known before the trial and must be estimated adap-
tively based on response data and biomarker measurements from already treated patients.
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To estimate the subgroups and their expected response rates to treatments, we propose a
random partition model. Assuming that all K biomarker measurements are continuous,
xik ∈ R, we construct patient subgroups by defining a partition of the biomarker space RK .
A partition is a family of subsets Π = {S1, S2, . . . , SM}, where M is the size of the partition
and Sm are the partitioning subsets such that Sm ∩ Sl = ∅ and ∪mSm = RK . The partition
of the biomarker sample space implies a partition of the patients into biomarker subgroups.
Patient i belongs to biomarker subgroup m if xi ∈ Sm. We will construct a prior probability
measure for Π in the next section. In the following discussion we will occasionally refer to
Sm as a subset of patients, implying the subset of patients that is defined by the partitioning
subset Sm.
We define a sampling model for yi conditional on xi and Π as
p(yi = 1 | zi = t,Π,xi ∈ Sm) = θt,m, (1)
where θt,m is the response rate of treatment t for a patient in subgroup Sm. Thus the joint
likelihood function for n patients is the product of n such Bernoulli probabilities, using θt,m
and (1 − θt,m) depending on the recorded outcomes yi. In each biomarker subgroup Sm,
let nm =
∑
i I(xi ∈ Sm) count the number of patients, nmt =
∑
i I(xi ∈ Sm, zi = t) the
number of patients assigned to treatment t, and nmty =
∑
i I(xi ∈ Sm, zi = t, yi = y) the
number of patients in group m assigned to t with response yi = y. Here I(·) is the indicator
function. Let y(n) = (y1, . . . , yn)
′, X(n) = {xi}ni=1, z(n) = (z1, . . . , zn)′, and θ = {θt,m; t =
1, . . . , T, m = 1, . . . ,M}. Then
p(y(n) |X(n), z(n),θ,Πr) =
∏
m
∏
t
θnmt1t,m (1− θt,m)nmt0 .
Adding a prior on Π and θ we complete (1) to define a 3-level hierarchical model
p(y(n),θ,Π |X(n), z(n)) ∝ p(y(n) |X(n), z(n),θ,Π) p(θ | Π) p(Π). (2)
The last two factors define the prior model for θ and Π. We assume θt,m | Π i.i.d∼ Beta(a, b) and
discuss the prior for Π next. Posterior inference on Π and θ provides learning on subgroups
and their treatment-specific response rates. Posterior probabilities for Π and θ are the key
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inference summaries that we will later use to define the desired adaptive trial design.
2.2 Random Biomarker Partition Π
We propose a tree-type random partition Π on the biomarker space RK to define random
biomarker subgroups. A partition is obtained through a tree of recursive binary splits. Each
node of the tree corresponds to a subset of RK , and is either a final leaf which defines one of
the partioning subsets Sm, or it is in turn split into two descendants. In the latter case the two
descendants are defined by first selecting a biomarker k and then splitting the current subset
by thresholding xik. The threshold splits the ancestor set into two components. A sequence
of such splits generates a partition of RK as the collection of the resulting subsets. For the
motivating breast cancer trial, we limit the partition to at most eight biomarker subgroups
in the random partition. We impose this constraint to limit the number of subgroups with
critically small numbers of patients, and therefore only allow three rounds of random splits.
An example is shown in Figure 1. The figure shows a realization of the random partition
with K = 2 biomarkers. In each round, we consider each of the current subsets and either do
not split it further with probability v0 or with probability vk choose biomarker k to split the
subset into two parts. If an ancestor subset S is split by the k-th biomarker, then the resulting
partition contains two new subsets, defined by {i : xik ≥ medk(S)} and {i : xik < medk(S)},
where medk(S) is the median of xik and is computed across all available data points in the
subset S. That is, medk(S) is a conditional median which can vary during the course of
the trial, as more data become available. In Figure 1 the sequence of splits is as follows.
We first split on xi1. In the second round the two resulting subsets are split on xi1 and xi2,
respectively. In a third round of splits, only one subset of the earlier four subsets is split on
xi1 again, three others are not further split.
Let Π be the sample space of all possible partitions based on the three rounds of splits.
For each partition Π ∈ Π, we calculate the prior probability p(Πr) based on the above
random splitting rules. For example, the partition Π in Figure 1 has prior probability
p(Π) ∝ v1 × v1 v2 × v0 v0 v0 v1, (3)
with the three factors corresponding to the three rounds of splits.
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We use a variation of the described probability model. The main rational is that, if a
biomarker is selected for an initial split, then it is desirable to augment the probability of
splitting it again at the subsequent levels in the tree. The goal is to facilitate the identification
of relevant subgroups maintaining the simplicity of the partition model. To implement this,
in each possible partition Π, we calculate K as the number of distinct biomarkers selected
in the three rounds of splits. We then add an additional penalty term proportional to φK to
the above prior probability of Π, so that the prior favors partitions that repeatedly split on
the same marker. For example, in Figure 1, the modified prior probability is
p(Π) ∝ v31 v2 v30 × φ2. (4)
Similarly, we can calculate the prior probability for any partition Π in Π. When φ = 1 the
two probability models that we described coincide while values of φ in (0, 1) allow one to tune
the concentration of over partitions that split over a parsimonious number of biomarkers.
2.3 Decision Rule for Patient Allocation
A major objective of the SUBA design is to assign future patients to superior treatments
based on their biomarker profiles and the observed outcomes of all previous patients. As-
suming that the outcomes of the first n patients have been observed, we denote by q(t,xn+1)
the posterior predictive probability of response under treatment t for an (n + 1)th patient
with biomarker profile xn+1. Denoting the observed trial data Dn = {y(n),X(n), z(n)}, based
on (2),
q(t,xn+1) ≡ p(yn+1 = 1 | xn+1, zn+1 = t,Dn)
=
∑
Πr∈Π
p(yn+1 = 1 | xn+1, zn+1 = t,Πr,Dn) p(Πr | Dn). (5)
The posterior probability p(Πr | Dn) can be computed as follows. Given a partition Πr =
(S1, . . . , SMr) ∈ Π, all n patients are divided into Mr biomarker subgroups. Recall the
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definition of nm, nmt and nmty from Section 2.1. The posterior distribution of Πr is
p(Πr | Dn) ∝ p(Πr) p(Dn | Πr) = p(Πr)
∏
m
∏
t
{∫ ∏
xi∈Sm
p(yi | xi, zi = t, θt,m) dp(θt,m)
}
,
where p(Πr) is the prior probability of partition Πr that can be calculated as in (4). Let
B(a, b) = Γ(a)Γ(b)/Γ(a + b) denote the beta function, and let Be(x; a, b) ∝ xa−1(1 − x)b−1
denote a beta p.d.f. With independent Be(x; a, b) prior distributions for the θt,m parameters
we can further simplify the above equation to
p(Πr | Dn) ∝ p(Πr)
∏
m
∏
t
{∫
θnmt1t,m (1− θt,m)nmt0 Be(θt,m; a, b) dθt,m
}
=
= p(Πr)
∏
m
∏
t
B(a+ nmt1, b+ nmt0)
B(a, b)
. (6)
The conditional probability p(yn+1 = 1 | xn+1, zn+1 = t,Π,Dn) is the integral of (1) with
respect to the Be(a+ nmt1, b+ nmt0) posterior on θt,m. Then
p(yn+1 = 1 | xn+1, zn+1 = t,Πr,Dn) =
∑
m
I(xn+1 ∈ Sm)
∫
θt,m dp(θt,m | Πr,Dn)
=
∑
m
I(xn+1 ∈ Sm) a+ nmt1
a+ b+ nmt
. (7)
Let m(xn+1,Π) index the partitioning subset with xn+1 ∈ Sm(xn+1,Π). The sum over m in
(7) reduces to just the term with m = m(xn+1,Π). Combining (6) and (7), we compute the
posterior predictive response rate of (n+ 1)th patient receiving treatment t in closed form
q(t,xn+1) =
∑
Πr∈Π
p(yn+1 = 1 | xn+1, zn+1 = t,Πr,Dn) p(Πr | Dn). (8)
Denote with z?n+1 ∈ Ω the treatment decision for the (n + 1)th patient. We choose
z?n+1 by adopting a minimum posterior predictive loss approach described in Gelfand and
Ghosh (1998). Under a variety of loss functions (such as the 0-1 loss), the optimal rule that
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minimizes the posterior predictive loss is
z?n+1 = arg max
t∈Ω
q(t,xn+1). (9)
See Raiffa and Schlaifer (1961) or Gelfand and Ghosh (1998) for details. Alternatively, one
could use the probabilities q(t,xn+1) in a biased randomization p(z
?
n+1 = t) ∝ q(t,xn+1)c, as
proposed in Thall and Wathen (2007).
2.4 The SUBA Design
Computing the posterior predictive response rates for all candidate treatments allows us to
compare treatments and monitor the trial accordingly. If one treatment is inferior to all other
treatments, that treatment should be dropped from the trial. If there is only one treatment
left after dropping inferior treatments, the trial should be stopped early due to ethical and
logistics reasons.
The SUBA design starts a trial with a run-in phase during which patients are equally
randomized to treatments. After the initial run-in, we continuously monitor the trial until
either the trial is stopped early based on a stopping rule, or the trial is stopped after reaching
a prespecified maximum sample size N .
We include rules to exclude inferior treatments and stop the trial early if indicated. Recall
that the biomarker space is RK . Consider the k-th biomarker and observed biomarker values
{x1k, . . . , xnk}. We define an equally spaced grid of size H0 between mink and maxk, where
mink and maxk are the observed smallest and largest values for that biomarker. Taking the
Cartesian product of these grids we then create a K−dimensional grid x˜ of size H = HK0 .
Let x˜h ∈ RK , h = 1, . . . , H, denote the list of all grid points. After an initial run-in phase
with equal randomization, we evaluate the posterior predictive response rate q(t, x˜h) for
treatment t for each x˜h. Any treatment t
? with uniformly inferior success probability
q(t∗, x˜h) < q(t, x˜h), for all h = 1, . . . , H and t 6= t?
is dropped from the trial. That is, we remove t? from the list of treatments, Ω ≡ Ω \ {t?}.
Also, if only one treatment is left in the trial, then the trial is stopped early.
Alternatively to the construction of the grid x˜, any available data set of typical biomarker
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values x˜h ∈ RK could be used. For large K this is clearly preferable. If such data were
available, it could also be used for an alternative definition of medk in the specification of
the splits in the prior for Πr discussed earlier.
The SUBA design consists of the following steps.
1. Initial run-in. Start the trial and randomize n < N patients equally to T treatments
in the set Ω.
2. Treatment exclusion and early stopping. Drop treatment t∗ if q(t∗, x˜h) <
q(t, x˜h) for all t 6= t∗ and h = 1, . . . , H. Set Ω = Ω \ {t∗}. If enrollment remains
active only for a single treatment t then stop the trial.
3. Adaptive patient allocation. Allocate patient (n+ 1) to treatment z?n+1 according
to (9). When the response yn+1 is available, go back to step 2 and repeat for patients
n+ 2, n+ 3, . . . , N .
4. Reporting patient subpopulations. Upon conclusion of the trial we report the
estimated partition Π together with the estimated optimal treatment allocations.
In step 4, summarizing the posterior distribution over random partitions and determining
the best partition over a large number of possible partitions Π is a challenging problem.
Following Medvedovic et al. (2004) we define an (N × N) association matrix GΠr of co-
clustering indicators for each partition Πr. Here G
Πr
ij is an indicator of patients i and j being
in the same subgroup with respect to the biomarker partition Πr. Dahl (2006) introduced
a least-squares estimate for random partitions using draws from Markov chain Monte Carlo
(MCMC) posterior simulation. Following their idea, we propose a least-square summary
ΠLS = argminΠr ||GΠr − Gˆ||2,
where Gˆ =
∑
rG
Πrp(Πr | Dn) is the posterior mean association matrix and ||A||2 denotes
the sum of squared elements of a matrix A. In words, ΠLS minimizes the sum of squared
deviations of between an association matrix GΠr and the posterior mean Gˆ.
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Alternatively one could report a partition that minimizes the average squared deviation,
averaging with respect to p(Πr | D). That is, minimize posterior mean squared distance
instead of squared distance to the posterior mean association matrix. While the earlier has
an appealing justification as a formal Bays rule, the latter is easier to compute.
3 Simulation Studies
3.1 Simulation Setup
We conduct simulation studies to evaluate the proposed design. The setup is chosen to mimic
the motivating breast cancer study. For each simulated trial, we fix a maximum sample size
of N = 300 patients in a three-arm study with three treatments t = 1, 2, 3. We assume that
a set of K = 4 biomarkers are measured at baseline for each patient and generate xik from
a uniform distribution on [−1, 1], i.e., xik ∼ Unif (−1, 1). The hyperprior parameters are
fixed as vk = 1/(K + 1), k = 0, 1, . . . , K, φ = 0.5, a = 1 and b = 1. That is, each biomarker
has the same prior probability of being selected for a split, and the response rates θt,m have
uniform priors. To set up the grid x˜ for the stopping rule we select H0 = 10 equally spaced
points on each biomarker subspace, and thus H = 10, 000 grid points in x˜. During the initial
run-in phase, n = 100 patients are equally randomized to three treatments.
Scenarios 1 through 6. We consider six scenarios and simulated 1, 000 trials for each
scenario. In the first two scenarios, we assume that biomarkers xi1 and xi2 are relevant to the
response, but not biomarkers xi3 and xi4. The simulation truth for the outcome yi is a probit
regression. Specifically, we assume that the true response rates for a patient with covariate
vector xi under treatments 1, 2 or 3 are θ1i = Φµ=0,σ=1.5(xi1 + 1.5xi2), θ2i = Φµ=0,σ=1.5(xi1),
or θ3i = Φµ=0,σ=1.5(xi1− 1.5xi2), respectively, where Φµ=0,σ=1.5 is the cumulative distribution
function (CDF) of a Gaussian distribution with µ = 0 and σ = 1.5. Figure 2 plots the
response rates under three treatments versus xi1 given different values of xi2. The red
lines represent treatment 1, black lines refer to treatment 2 and green lines to treatment
3. Treatment 3 is always the most effective arm when xi2 < 0, the three treatments have
equal success rates when xi2 = 0, and treatment 1 is superior when xi2 > 0. In summary,
the optimal treatment is a function of the second biomarker, xi2. That is, xi2 identifies the
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optimal treatment selection. The response rates of three treatments increase with xi1, but
the ordering of the three treatments does not change varying the first biomarker. Therefore,
xi1 is only predictive of response, but ideally should not be involved for treatment selection.
To assess the performance of SUBA under this setup, we select two scenarios. In an over-
simplified scenario 1, we assume that all the patients have xi2 = 0.8. Thus, treatment 1 is
more effective than 2, which in turn is more effective than 3. In scenario 2, we do not fix the
values of xi2 and randomly generate all biomarker values.
In scenario 3, we assume that biomarkers 1, 2 and 3 are related to the response and
there are interactions. The true response rates under treatments 1, 2, or 3 are θ1i =
Φµ=0,σ=1.5(xi1+1.5xi2−0.5xi3+2xi1xi3), θ2i = Φµ=0,σ=1.5(−xi1−2xi3), or θ3i = Φµ=0,σ=1.5(xi1−
1.5xi2 − 2xi1xi2), respectively. Figure 3 plots the response rates under three treatments ver-
sus (xi1, xi2) given xi3 = 0.6 (Figure 3a) and given xi3 = −0.6 (Figure 3b). Here, all three
markers are predictive of the ordering of the treatment effects in a complicated fashion.
We design scenarios 4 and 5 with treatment 3 being uniformly inferior to treatments 1 and
2. We assume that the response rates under treatments 1 and 2 are θ1i = Φµ=0,σ=1.5(x
2
i1/2 +
xi1xi2/2) or θ2i = Φµ=0,σ=1.5(x
2
i2/2 − xi1xi2/2). The implied minimum response rate for
treatments 1 and 2 is 0.37 and the response rates of treatment 1 and 2 are close for all
biomarker values (differences range from -0.24 to 0.24 with the first quantile across biomarker
profiles equal to -0.06 and the third quantile equal to 0.09). We assume θ3i = 0.15 in scenario
4 and θ3i = 0.3 in scenario 5, thus θ3i ≤ min(θ1i, θ2i) for all xi1 and xi2. So we can expect
that treatment 3 should be excluded in both scenarios.
Finally, Scenario 6 is a null case, in which no biomarkers are related to response. We
assume that the response rates under the three treatments for all the patients are the same
at 40%, that is, θ1i = θ2i = θ3i = 0.4.
Comparison. For comparison, we implement a standard design with equal randomization
(ER), an outcome-adaptive randomization (AR) design, and a design based on a probit re-
gression model (Reg). In the ER design, all patients are equally randomized to the three
treatments and their responses are generated from Bernoulli(θti) for patient i receiving treat-
ment t, t = 1, 2, 3 and i = 1, . . . , N . The values of θti are defined by the Gaussian CDFs given
above. Under the AR design, we assume that three predefined biomarker subgroups are fixed
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before the trial (similar to the BATTLE trial Kim et al. (2011)). We assume that the three
subgroups are defined as {xi1 < −0.5}, {−0.5 ≤ xi1 ≤ 0.5} and {xi1 > 0.5}, using the quar-
tiles of the empirical distribution of biomarker xi1 as thresholds. Apparently, these subgroups
are wrongly defined and do not match the true response curves in scenarios 1-6. The mis-
match is deliberately chosen to evaluate the importance of correctly defining subgroups. Let
ptb be the response rate of treatment t in subgroup b, and ntb the total number of patients re-
ceiving treatment t in subgroup b, t = 1, 2, 3 and b = 1, 2, 3. For this design we use the model
yi | xi ∈ b ∼ Binomial(ntb, ptb). With a conjugate beta prior distribution beta(1,1) on ptb, we
easily compute the posterior of ptb as ptb | D ∼ beta(ntb1 + 1, ntb−ntb1 + 1), where ntb1 is the
number of patients who responded to treatment t in subgroup b. Then under the AR design,
we first equally randomize 100 patents to the three treatments, and adaptively randomize the
next 200 patents sequentially. The AR probability for a future patient in subgroup b equal
pˆtb/(pˆ1b + pˆ2b + pˆ3b), where pˆtb is the posterior mean (ntb1 + 1)/(ntb + 2), alternatively other
summaries of the (p1b, p2b, p3b) posterior can be used to adapt treatment assignment Thall
and Wathen (2007). Under the Reg design, we model binary outcomes using a probit regres-
sion. In the probit model, the inverse standard normal CDF of the response rate is modeled
as a linear combination of the biomarkers and treatment, p(yi = 1 | zi,xi) = Φ(β0zi +β′1xi).
The parameters β0 and β1 = (β11, . . . , β1k) are obtained using maximum likelihood estima-
tion. Under the Reg design, we randomize the first 100 patients with equal probabilities to
the three treatments, and then assign the next 200 patients to the treatment with estimated
best success probability, sequentially.
3.2 Simulation Results
Response rates. Define the overall response rate (ORR) as
ORR =
1
N − n
N∑
i=n+1
I(yi = 1),
which is the proportion of responders among those patients who are treated after the run-in
phase. We summarize ORR differences between SUBA versus ER, AR, and Reg for each
scenario in Figure 4. In our comparisons we use the same burn in period n = 100 across
designs.
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For scenarios 2 and 3, SUBA outperforms ER, AR and Reg with higher ORR in almost
all the simulated trials. The ER and AR designs perform similarly. This suggests that no
gains are obtained with AR when the biomarker subgroups are wrongly defined, confirming
that for AR it is essential an upfront appropriate selection of the biomarker subgroups. In
scenarios 1, 4 and 5, SUBA and Reg are preferable to ER and AR. SUBA exhibits a larger
ORR value than Reg in 676 of 1,000 simulations in scenario 1, in 612 of 1,000 simulations
in scenario 4 and in 605 of 1,000 simulations in scenario 5. In scenario 6, the true response
rates are constant and not related to biomarkers, and the four designs show similar ORRs
distribution across 1,000 simulations.
Early stopping. Table 1 reports the average number of patients under the SUBA design.
When a trial is stopped early by SUBA, there must be one last treatment left which are
considered more efficacious than all the removed treatments. For a fair comparison with
ER, AR and Reg which do not include early stopping, summaries in Table 2 are based on
assignment of all remaining patients, until the maximum sample size N , to that last active
arm.
Scenario 1 2 3 4 5 6
# of patients 245.28 299.41 300.00 167.63 215.07 209.52
Table 1: The average numbers of patients needed to make the decision of stopping trials
early in 1,000 simulated trials in scenarios 1-6.
Treatment assignment. We compute the average number of patients (ANP) assigned
to treatment t after the run-in phase by the three designs. Denote NPdt as the number of
patients assigned to treatment t in dth simulated trial after the run-in phase, i.e., NPdt =∑N
i=n+1 I(z
?
i = t), t = 1, 2, 3 and d = 1, . . . , 1000. Thus
ANPt =
1
1000
1000∑
d=1
NPdt .
Table 2 shows the results. In scenario 1, treatment 1 is always the most effective arm since
the second biomarker is fixed at 0.8 (see Figure 2). We can see that most of the patients
are allocated to treatment 1 in scenario 1 by SUBA. Scenario 6 is a null case in which the
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biomarkers are not related to response rates and the response rates across treatments are
the same, so the patients allocation by SUBA is similar as ER, AR and Reg.
Scenario ER AR Reg SUBA
Subset 1 2 3 1 2 3 1 2 3 1 2 3
1 / 66.76 66.60 66.64 83.02 65.35 51.63 119.46 70.13 10.41 177.11 18.67 4.22
2
S01 33.49 33.09 33.24 33.37 33.19 33.25 35.24 32.88 31.69 72.57 18.37 8.88
S02 33.27 33.51 33.40 33.41 33.25 33.53 35.42 33.01 31.76 8.63 17.79 73.77
3
S01 19.49 19.09 19.29 22.21 17.63 18.03 18.65 16.40 22.81 41.11 8.94 7.82
S02 25.23 25.17 25.35 21.13 26.81 27.80 24.10 21.86 29.79 13.67 35.91 26.17
S03 22.05 22.34 22.00 24.61 20.52 21.26 21.27 18.99 26.12 11.33 11.54 43.52
4
S01 33.26 33.11 33.44 43.01 42.32 14.49 51.81 48.00 0 52.76 46.96 0.10
S02 33.50 33.49 33.20 42.32 43.46 14.41 51.75 48.44 0 50.78 49.29 0.11
5
S01 33.26 33.11 33.44 39.14 38.49 22.19 51.51 48.25 0.05 51.13 47.05 1.63
S02 33.50 33.49 33.20 38.29 39.32 22.58 51.22 48.92 0.05 47.07 51.53 1.59
6 / 66.76 66.60 66.64 66.66 66.89 66.46 65.04 67.84 67.12 66.90 64.20 68.90
Table 2: The average numbers of patients (ANPs) assigned to three treatments after the
run-in phase in three defined subsets by ER, AR, Reg and SUBA in 1,000 simulated trials
in scenarios 1-6.
In scenario 2, we separately report the average numbers of patients assigned to three
treatments after the run-in phase, among those whose second biomarker is positive or nega-
tive. We separately report these two averages to demonstrate the benefits of using the SUBA
design since depending on the sign of the second biomarker, different treatments should be
selected as the most beneficial and effective ones for patients. When the second biomarker
is positive, treatment 1 is the most superior arm; when the second biomarker is negative,
treatment 3 is the most effective arm according to our simulation settings. From Table 2,
among the 200 post-runin patients, about 100 patients have (xi2 > 0) values of the second
biomarker. In Table 2 we use S01 = {i : xi2 > 0} and S02 = {i : xi2 < 0} to denote sets of
patients. Think of {S01 , S02} as a partition in the simulation truth. Among patients in S01 ,
Table 2 reports that an average of approximately 73 of them are allocated to treatment 1,
18 to treatment 2, and 9 to treatment 3. For those in S02 , 9 are allocated to treatment 1,
18 to treatment 2, and 74 to treatment 3. Most of the patients are assigned to the correct
superior treatments according to their biomarker values, highlighting the utility of the SUBA
design. In contrast, ER, AR and Reg designs assign far fewer patients to the most effective
treatments. These results and, similarly Figure 4, shows the utility of the SUBA approach.
In scenario 3, biomarkers 1, 2 and 3 are related to the response. In a similar fashion,
we report patient allocations by breaking down the numbers according to three subsets
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that are indicative of the true optimal treatment allocation depending on the biomarker
values. Denote θ¯1i = xi1 + 1.5xi2 − 0.5xi3 + 2xi1xi3, θ¯2i = −xi1 − 2xi3, and θ¯3i = xi1 −
1.5xi2 − 2xi1xi2. According to the simulation truth, we consider three sets S01 , S02 and S03 ,
defined as S01 = {i : θ¯1i > θ¯2i and θ¯1i > θ¯3i}, S02 = {i : θ¯2i > θ¯1i and θ¯2i > θ¯3i} and
S03 = {i : θ¯3i > θ¯1i and θ¯3i > θ¯2i}. Under this assumption, the best treatment for patients
in set S0t is treatment t according to the simulation truth. Table 2 reports the simulation
results for S01 , S
0
2 and S
0
3 . We can see most of the patients are assigned to the correct superior
treatments. In contrast, the ER, AR and Reg designs fail to do so.
In scenarios 4 and 5, biomarkers 1 and 2 are related to the response. Since treatment 3
is inferior to treatments 1 and 2, the biomarker space is only split to two sets S01 and S
0
2
according to simulation truth. Denote θ¯1i = x
2
i1/2 + xi1xi2/2, θ¯2i = x
2
i2/2 − xi1xi2/2. So
S01 = {i : θ¯1i > θ¯2i} and S02 = {i : θ¯2i > θ¯1i}. Table 2 again shows that SUBA assigns more
patients to their corresponding optimal treatments than ER and AR designs, but performs
similar as Reg. Scenarios 4-5 are two challenging cases, in which the dose-response surfaces
are “U”-shaped (plots not shown) and treatments 1 and 2 have similar true responses rates
for most biomarker values. Treatment 3 is much less desirable to treatments 1 and 2, and
is excluded by SUBA and Reg quickly across most of the simulations. Both designs assign
similar numbers of patients on average to treatments 1 and 2. However, both designs assign
a considerable number of patients to suboptimal treatments. For example, in both scenarios
50% of the patients received a suboptimal treatment, which could be caused by false negative
splits that failed to capture the superior subgroups for those patients. Nevertheless, SUBA
is still markedly better than the ER and AR designs in these scenarios.
In summary, SUBA continuously learns the response function to pair optimal treatments
with targeted patients and can substantially outperform ER, AR and Reg in terms of OOR.
Posterior estimated partition. Figure 6 shows the least-square partition ΠLS in an
arbitrarily selected trial for scenarios 2 and 3. The number in each circle represents the
biomarker used to split the biomarker space. In scenario 2, biomarkers 1 and 2 are related
to response rate. Treatment 1 is the best treatment when the second biomarker is positive
and treatment 3 is the best one when the second biomarker is negative. The least-square
partition ΠLS uses biomarker 2 to split the biomarker space in the first round of split, which
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corresponds to the simulation truth. In scenario 3, biomarkers 1, 2, and 3 are related to
response rate and the least-square partition ΠLS uses these true response-related biomarkers
to split as well.
3.3 Sensitivity Analysis
To evaluate the impact of the maximum sample size on the simulation results, we carried
out a sensitivity analysis with N = 100, 200, 300 in scenario 1, with first n = 100 patients
equally randomized. Recall that in scenario 1, treatment 1 has a higher response rate than
treatments 2 and 3, regardless of their biomarker values. Therefore the effect of sample size
on the posterior inference can be easily evaluated.
Figure 5 plots the histogram of differences between treatments qN+1(1,xn+1)−qN+1(2,xn+1)
and qN+1(1,xn+1)− qN+1(3,xn+1) after N = 100, 200, or 300 patients have been treated in
the trial. When N = 100, treatment 1 is reported as better than treatment 2 in 752 of
1,000 simulations; when N = 200, treatment 1 is better than treatment 2 in 838 of 1,000
simulations; when N = 300, treatment 1 is better than treatment 2 in 884 of 1,000 simula-
tions. The more patients treated, the more precise the posterior estimates and more accurate
assignments for future patients. Similar patterns are observed for the comparison between
treatments 1 and 3.
We also varied the values φ and conducted sensitivity analysis with φ = 0.2, 0.5, 0.8 using
scenario 2. Table 3 shows the average numbers of patients needed to make the decision of
stopping trials early and the average numbers of patients assigned to three treatments after
the run-in phase in two defined subsets. In summary, the reported summaries vary little
across the considered hyperparameter choices, indicating robustness with respect to changes
within a reasonable range of values.
φ = 0.2 φ = 0.5 φ = 0.8
# of patients 298.10 299.41 299.15
Subset 1 2 3 1 2 3 1 2 3
S01 71.66 19.09 9.06 72.57 18.37 8.88 72.21 18.50 9.11
S02 8.64 18.50 73.05 8.63 17.79 73.77 8.79 18.31 73.09
Table 3: The average numbers of patients needed to make the decision of stopping trials early
and patient allocation breakdowns in scenario 2 with different values of φ = 0.2, 0.5, 0.8.
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4 Discussion
We demonstrated the importance of subgroup identification in adaptive designs when such
subgroups are predictive of treatment responce. The key contribution of the proposed model-
based approach is the construction of the random partition prior p(Π) which allows a flexible
and simple mechanism to realize subgroup exploration as posterior inference on Π. The
Bayesian paradigm facilitates continuous updating of this posterior inference as data becomes
available in the trial. The proposed construction for p(Π) is easy to interpret and, most
importantly, achieve a good balance between the required computational burden for posterior
computation and the flexibility of the resulting prior distribution. The priors of θt,m are i.i.d
Beta(a, b), with a = b = 1, i.e., a uniform prior in our simulation studies. If desired, this prior
can be calibrated to reflect the historical response rate of the drug. The i.i.d assumption
simplifies posterior inference. Alternatively, one could impose dependence across the θ’s; for
example, one could assume that adjacent partition sets have similar θ values.
The proposed SUBA design focuses on the treatment success for the patients who are
enrolled in the current trial by identifying subgroups of patients who respond most favorably
to each of the treatments. One could easily add to the SUBA algorithm a final recommen-
dation of a suitable patient population for a follow-up trial, such as ΠLS. Other directions
of generalization include an extension of the models to incorporate variable selection, when
a large number of biomarkers are measured.
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Figure 1: An illustration of p(Π) with three rounds splits. The example shows that
with three rounds of split, the initial space of two biomarkers is partitioned into five sets
{UU11, UL11, LL12, LUU121, LUL121}.
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Figure 2: Display of Scenario 2. The probabilities of response versus the measurements of
the first biomarker given fixed values of the second biomarker. Red, black and green lines
represent three treatments 1, 2 and 3 respectively.
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(a) When 3rd biomarker=0.6 (b) When 3rd biomarker=-0.6
Figure 3: Display of Scenario 3. The probabilities of response versus the measurements of
the first and the second biomarkers given the fixed values of the third biomarker at 0.6 (a)
and -0.6 (b). Red, black and green lines represent three treatments 1, 2 and 3 respectively.
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Figure 4: The overall response rate (ORR) comparisons among the ER, AR, Reg and SUBA
designs in 1,000 simulated trials in all six scenarios. We plot the ORR differences between
SUBA and ER, AR, Reg respectively in each scenario. The blue color represents the ORR
of SUBA is higher than ER, AR or Reg; the red color represents lower.
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Figure 5: The histogram of qN+1(1)−qN+1(2) and qN+1(1)−qN+1(3) when N = 100, 200, 300.
The right side of red vertical line indicates that the posterior predictive rate of treatment 1
is higher than treatment 2 or treatment 3.
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Figure 6: The tree-type least-square partition by SUBA design in one simulated trial in
scenarios 2 and 3. The number in the circle represents the biomarker used to split the
biomarker space.
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